Merck & Company, IncNYSE: MRK
Health Care · Pharmaceuticals
$115.54
-0.29%
Vol: 1.5M
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours. The FDA approval of KEYTRUDA/KEYTRUDA QLEX plus WELIREG in adjuvant clear cell renal cell carcinoma occurred on Friday June 12, roughly 72 hours before June 15, exceeding the 48-hour window.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Merck completed Terns Pharmaceuticals acquisition on May 5; TroFuse-005 endometrial cancer trial met OS and PFS endpoints; ASCO 2026 data May 29-Jun 2.Positive▶
Merck completed the Terns Pharmaceuticals acquisition on May 5, with EPS impact of ~$0.12 over the remainder of 2026. The TroFuse-005 trial evaluating Sacituzumab Tirumotecan (Sac-TMT) met primary endpoints of Overall Survival and Progression-Free Survival in patients with advanced/recurrent endometrial cancer - a key oncology win. Merck received FDA approval for IDVYNSO for HIV. The company will present extensive oncology data at ASCO 2026 (May 29-June 2), including five-year follow-up on intismeran autogene + KEYTRUDA in resected high-risk melanoma. On May 8, Merck issued a statement on Daiichi Sankyo's ADC manufacturing/supply update, noting no material financial impact (charges previously reserved). Citigroup PT $125 (May 6). Stock at $113.95, market cap $281B.
May 20Merck completes Terns acquisition and posts positive TroFuse-005 endometrial cancer trial ahead of major ASCO 2026 oncology data drop.Positive▶
Merck closed its acquisition of Terns Pharmaceuticals, adding to a pipeline diversification effort as the company prepares for Keytruda's eventual LOE. Its experimental ADC sacituzumab tirumotecan (sac-TMT) hit both primary endpoints (OS and PFS) in the late-stage TroFuse-005 trial in advanced/recurrent endometrial cancer, an important readout for one of Merck's leading post-Keytruda assets. The FDA also approved IDVYNSO (doravirine/islatravir), a once-daily two-drug HIV-1 regimen for virologically suppressed adults. Q1 2026 revenue grew 5% YoY to $16.3B led by oncology and animal health, and 2026 guidance was raised. Merck plans to present 100+ abstracts at ASCO 2026 (May 29-June 2), including five-year KEYNOTE-942 melanoma data and final KEYNOTE-522 TNBC analysis. Stock at $112.11 with consensus Buy and PT ~$129.74.
May 19Merck completes Terns acquisition and wins FDA approval for IDVYNSO HIV regimenPositive▶
Merck completed its cash tender offer for Terns Pharmaceuticals on May 5, 2026, at $53.00 per share, bringing in TERN-701, an FDA Breakthrough Therapy-designated treatment for chronic myeloid leukemia. The FDA also approved IDVYNSO (doravirine/islatravir), the first and only non-INSTI, tenofovir-free, once-daily two-drug HIV regimen, which demonstrated non-inferior efficacy versus Biktarvy in a Phase 3 head-to-head trial. Merck's Q1 2026 sales reached $16.29 billion, beating consensus of $15.85 billion driven by Keytruda's continued double-digit growth across multiple cancer indications. The TroFuse-005 trial of Sac-TMT met primary endpoints in advanced endometrial cancer. Morgan Stanley raised its PT to $112 from $109 on May 1. Risk: Keytruda concentration and patent cliff exposure later this decade.
May 18Merck showcases long-term oncology data at ASCO 2026 on May 16, with Keytruda combination trials and upcoming June 1 Oncology Investor Event in focus.Positive▶
Merck presented new long-term data across its oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) 2026 annual meeting on May 16, 2026. The company is also scheduled to hold an Oncology Investor Event on June 1, 2026 to coincide with ASCO. This builds on Q1 results that saw raised full-year sales guidance to $65.8-67.0B and total sales of $16.3B. Keytruda revenue hit $8.0B in the quarter, and the company is closing its acquisition of Terns Pharmaceuticals to expand its hematology pipeline. Risks remain around Keytruda patent expiration and competition.
May 15Merck completed $5.8B Terns Pharmaceuticals acquisition while ASCO 2026 oncology data and raised FY guidance support shares.Positive▶
Merck completed its tender offer for Terns Pharmaceuticals on May 4, 2026, acquiring TERN-701 (FDA-designated Breakthrough Therapy for CML) with a roughly $5.8B R&D charge ($2.35/share). Q1 2026 revenue rose 5% to $16.3B, beating estimates, and FY 2026 sales guidance was raised to $65.8-67.0B, driving an 8% post-earnings surge. Merck unveiled long-term Keytruda data and a clinical collaboration with Erasca (ERAS-0015 + Keytruda) at ASCO 2026, plus positive Phase 2 data with Inhibrx's INBRX-106. Morgan Stanley raised its price target to $112 from $109 on May 1. A Gardasil vaccine safety trial is scheduled for late July, posing a litigation overhang. Shares trade near $113 with broadly bullish coverage (18 Buy / 11 Hold).
May 14Merck shares rose ~1% on May 13 to $113.45 as the company continued integrating its just-closed Terns Pharmaceuticals acquisition and prepared more than 100 oncology abstracts for ASCO 2026 (May 29-June 2).Positive▶
On May 13, 2026, Merck stock traded up 0.96% to $113.45 in a $111.55-$113.99 range as investors digested the just-completed acquisition of Terns Pharmaceuticals (closed May 5, ~86.36% of shares tendered). Terns brings TERN-701, an oral allosteric BCR::ABL1 TKI with FDA Breakthrough Therapy Designation for adults with Philadelphia-chromosome positive chronic myeloid leukemia, strengthening Merck's oncology pipeline beyond Keytruda. The company also pre-announced more than 100 abstracts across 25+ cancer types for ASCO 2026 (May 29-June 2), including long-term data updates from its core oncology franchise. Q1 2026 results showed $16.286B in sales with Keytruda generating $8.0B, though the quarter posted a GAAP net loss of $4.24B from acquisition-related charges. Risk: looming Keytruda patent-cliff overhang and pipeline-replacement execution remain the central long-term concern.
May 13Merck acquires Terns Pharmaceuticals for $6.7B cash on May 5; Q1 revenue beats at $16.3B on Keytruda (+8%) and Winrevair (+88%) growth.Positive▶
Merck acquired Terns Pharmaceuticals on Tuesday, May 5, 2026 for $6.7 billion in cash, expanding its oncology and pipeline assets. The company also disclosed Erasca s AURORAS-1 clinical trial pact and supply agreement with Merck. Q1 2026 revenue reached $16.3B, beating estimates, with KEYTRUDA sales rising 8% and WINREVAIR sales surging 88% year-over-year. Morgan Stanley raised its price target to $112 from $109 on May 1, 2026. According to 18 analysts, Merck has a Buy consensus rating with a 2026 price prediction of $125. MRK traded at $111.89 on May 8 with a 52-week range of $73.31-$125.14. The company continues to face patent expirations and competitive pressure but is actively expanding its oncology collaborations.
May 12Merck closed its acquisition of Terns Pharmaceuticals on May 5, adding BCR::ABL1 inhibitor TERN-701 with a ~$5.8B R&D charge (~$2.35/share, $0.12 EPS drag in 2026).Positive▶
On May 5, 2026, Merck completed the tender-offer acquisition of Terns Pharmaceuticals at $53.00 per share (approximately 86.36% of Terns shares tendered), gaining TERN-701, an oral allosteric BCR::ABL1 tyrosine kinase inhibitor with FDA Breakthrough Therapy Designation for Philadelphia chromosome-positive chronic myeloid leukemia. The deal results in an approximately $5.8B charge to R&D (about $2.35 per share) and an expected $0.12 negative impact on 2026 GAAP/non-GAAP EPS. The acquisition diversifies Merck's oncology pipeline ahead of Keytruda LOE pressure. Merck is also restructuring its human-health division into two parts. Shares traded near $112.85 on May 11 with a Buy consensus from 18 analysts and a median PT of $130.
May 11Merck closes $6.7B Terns Pharmaceuticals acquisition, gaining TERN-701 with FDA Breakthrough Therapy Designation for CMLPositive▶
Merck completed its acquisition of Terns Pharmaceuticals on May 5, 2026 for $6.7B in cash. The deal centers on TERN-701, which holds FDA Breakthrough Therapy Designation for adults with Philadelphia chromosome-positive chronic myeloid leukemia. Merck Animal Health separately selected Salesforce's Agentforce Life Sciences for customer engagement on May 6. Analyst consensus on MRK is Buy as of May 11, 2026, with shares trading near $111.81. Merck previously raised FY26 sales guidance to $65.8B-$67.0B despite a Q1 net loss tied to a prior charge.
May 8Merck completes Terns Pharmaceuticals acquisition on May 8; FDA approves once-daily IDVYNSO HIV regimen.Positive▶
Merck completed its acquisition of Terns Pharmaceuticals for $5.8 billion on May 8, 2026, adding TERN-701 with FDA Breakthrough Therapy Designation for chronic myeloid leukemia. The same day, the FDA approved IDVYNSO, a new two-drug single-tablet HIV regimen. Merck reported strong Q1 2026 results beating consensus on EPS and revenue, raising FY26 adjusted EPS guidance to $5.04-$5.16. The 12-month consensus price target is $125.29.
May 6Merck completes $6.7B acquisition of Terns Pharmaceuticals on May 5, adding TERN-701 oncology asset.Positive▶
Merck completed the acquisition of Terns Pharmaceuticals on May 5, 2026, for $53 per share in all-cash deal. The acquisition adds TERN-701, a novel oral BCR::ABL1 tyrosine kinase inhibitor granted FDA Breakthrough Therapy Designation for Philadelphia chromosome-positive chronic myeloid leukemia. Merck reported strong Q1 2026 results with $16.29B in revenue and KEYTRUDA/KEYTRUDA QLEX sales of $8.0B (+12% growth). FDA also approved IDVYNSO for HIV-1 and NUMELVI for canine allergic dermatitis.
May 5Merck completes Terns Pharma acquisition for $6.7B; raises FY26 guidance to $65.8-67.0BPositive▶
Merck & Co. completed the acquisition of Terns Pharmaceuticals for $53/share (86.36% tendered) by May 4, 2026 tender offer expiration, totaling approximately $6.7B. TERN-701, an investigational chronic myeloid leukemia treatment, recently earned FDA Breakthrough Therapy Designation. Merck posted strong Q1 results beating estimates on Keytruda strength and new launches (WINREVAIR, IDVYNSO new HIV treatment). The company raised FY26 revenue guidance to $65.8–67.0B. Market cap $279.42B at $113.11/share (P/E 31.57). Multiple analyst Buy ratings (BMO Capital, Guggenheim, Scotiabank). Strategic portfolio diversification underway.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $1,119.42 | +7.47% | +5.4% | 23.4x | 0.48 | $928.9B |
| JNJJOHNSON | $237.09 | +2.31% | +1.2% | 18.2x | 0.26 | $557.8B |
| MRKMERCK | $115.54 | -0.29% | +3.0% | 12.2x | 0.20 | $286.2B |
| PFEPFIZER | $26.31 | +1.39% | +2.5% | 9.2x | 0.30 | $147.9B |
| BMYBRISTOL | $56.21 | -5.61% | +3.9% | 9.7x | 0.26 | $121.6B |
| ZTSZOETIS | $80.55 | +0.60% | +3.0% | 10.8x | 0.86 | $33.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.